59Shane Schaffer, Co-founder, Chairman, and CEO of Cingulate Therapeutics in Kansas City, Kansas, leads a Phase 3 clinical-stage biopharmaceutical company known for its innovative next-generation pharmaceutical products. The company focuses on Attention Deficit/Hyperactivity Disorder (ADHD) and other areas, such as anxiety disorders and insomnia.
A veteran with 25 years in the pharmaceutical industry, he is an expert in drug development and commercialization. His leadership and entrepreneurial skills have been pivotal in product launches, brand planning, joint venture brand management, life cycle management, and market development, making him a distinguished figure in biopharmaceutical.
He earned his doctoral degree in Pharmacy from the University of Kansas in 1999 and subsequently completed a postdoctoral fellowship at Rutgers University's College of Pharmacy. During his fellowship, he worked with Pfizer Worldwide Marketing and Morris Plains, gaining significant experience in marketing and research management.
While at Pfizer Worldwide Marketing in New York, he took on the role of Marketing Manager, where he developed pre-launch strategies and initiated the Global Communications Intranet to foster better communication between medical and marketing teams. He also played a key role in the Pfizer Medical and Academic Partnership in Pain Management.
In New Jersey at Morris Plains, he served as Project Manager and External Research Manager, leading advanced sales training and managing the initiation of Phase IV Medical Research across all marketed brands.
Throughout his career, he held several significant managerial roles at Pfizer, Novartis, and Sanofi. At Novartis, he was appointed Product Manager for the Ritalin® LA and Focalin™ segments. He successfully launched these products with notable market penetration and recognition, including the Novartis Business Excellence Award for his strategic execution.
After Novartis, he continued to make substantial impacts at Sanofi, where he played a crucial role during the company's mergers and joint ventures, particularly with the successful management of Avapro and Avalide and later with Hyalgan, Eligard, and Arixtra, enhancing sales strategies and professional relationships.
In 2008, he joined M|C Communications LLC in Boston as a Consultant, where he led the development of business opportunities for major pharmaceutical firms. In July 2009, he founded Sabre Scientific Solutions, LLC, which provides consulting services in commercials, clinical strategies, product launches, and leadership.
Driven by a passion for addressing ADHD, he established Cingulate Therapeutics LLC in January 2013. The company focuses on innovative drug-delivery technologies for ADHD and anxiety disorders. The company has partnered with Indegene to market its oral ADHD medication, CTx-1301, and is preparing to submit a new drug application to the FDA by mid-2025.
Beyond his professional endeavors, Shane Schaffer is committed to philanthropy. He actively supports the Folds of Honor Charity, which provides educational scholarships to children of fallen or disabled military personnel. This demonstrates his dedication to both healthcare innovation and community support.